ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • CHIPO Partner Highlight: Hepatitis Aid Organization

    … health workers, specifically those working in maternal health clinics. We have been able to engage cultural leaders for social mobilization. We have been also able to engage religious leaders. I mean it's quite a lot.   We have many partnerships in academia, in Africa, in Uganda, in India, and we are trying to see how we can bridge the gap to inform our proposals and decision making. We have initiated the parliamentary health forum on hepatitis in Uganda, which supports hepatitis advocacy and seeing that things are really working on at the parliamentary level. We are also supporting the Ministry of Health in Uganda at the National Technical Working Group, where we have representation. We have a network of patients that we are working on in partnership with the National Organization for People Living with Hepatitis, and we are looking to see how we can support the patients in Uganda better. So, we are doing quite a number of things. We are doing advocacy at the community level, but also on a national level.   We have been able to push for inclusion of hepatitis services on the Global Fund and PEPFAR (President’s Emergency Plan for AIDS Relief) fund in Uganda, and right now we are pushing for even more funding because previously they started funding the maternal child health testing for pregnant women, but we are now pushing for more than just testing for pregnant women. Also, with the new WHO guidelines on treatment, we are saying that we need to budget for treatment for these mothers. We need to do something, more support. We have also been part of campaigns that have pushed for national domestic funding for hepatitis, so we are doing quite a number.   My next question is if you could explain some of these partnerships in more detail…   So, I can give some more light on the partnerships. We are trying to see that our partnerships are diverse in terms of what we are doing with them. We are looking at partnerships with CSO's (civil society organization) or

    http://www.hepb.org/blog/chipo-partner-highlight-hepatitis-aid-organization/
  • CHIPO Partner Highlight: Hepatitis B Initiative of Washington, D.C.

    The Coalition Against Hepatitis for People of African Origin (CHIPO) is a community coalition that is co-founded and led by the Hepatitis B Foundation and is made up of organizations and individuals who are interested in addressing the high rates of hepatitis B infection among African communities in the U.S. and globally. Over the past year, CHIPO has grown its membership to include over 50 community-based organizations and federal agencies, all of which are working to meet the common goals of raising awareness about hepatitis B among African communities, and increasing rates of screening, vaccination, and linkage to care. This month, we are excited to highlight the work of one of our partners, the Hepatitis B Initiative of Washington, DC, (HBI-DC), and their new Deputy Executive Director, Sandra Ashford. Please enjoy a recent interview with Sandra, as she describes her work, including successes and challenges, and the positive impact HBI-DC has had by expanding their organization and mission. Could you please introduce yourself and your organization? Hello, my name is Sandra Ashford. The current Deputy Executive Director for the Hepatitis B Initiative, Jane Pan, will soon be retiring, and I'll be stepping into the role. I started out in hepatitis B as a Latino outreach coordinator and then worked with the Fairfax County, Virginia, health department. I have also worked with IPHI (Institute for Public Health Innovation) for COVID. Can you tell me about HBI-DC? HBI-DC was founded by Leslie Oh, whose mom and brother died in the same year of hepatitis B-related complications. After experiencing the pain of losing her family members she decided that she did not want anybody else to go through that struggle. As a result, she started HBI Boston, where she was studying public health at Harvard University at the time. While in school she would pass out informational pamphlets about hepatitis and engage in other advocacy efforts. She moved to Washington D.C. in 2006 and

    http://www.hepb.org/blog/chipo-partner-highlight-hbi-dc/
  • Reduce Liver Cancer Risk and Join a Liver Cancer Awareness Twitter Chat Oct. 12

    On Thursday, Oct. 12, representatives from Hepatitis B Foundation, CDC's Division of Viral Hepatitis, and NASTAD (the National Alliance of State and Territorial Aids Directors) will co-host a twitter chat at 2 p.m. EST using the hashtag #liverchat. Also participating is special guest Katherine McGlynn, PhD of the National Cancer Institute. Dr. McGlynn is a Senior Investigator at the National Cancer Institute, Division of Cancer Epidemiology & Genetics, Metabolic Epidemiology Branch. She is a researcher and expert in hepatocellular carcinoma. Below are questions scheduled to be discussed during the chat. How can you contribute to the conversation?  Share any resources or strategies you have that raise awareness and improve liver cancer surveillance. Join the conversation with the hashtag #liverchat. Q1: What is primary liver cancer and why is raising awareness so important? Q2: What are the risk factors for liver cancer and why should people with viral hepatitis worry? Q3: What are some strategies to help prevent viral hepatitis and liver cancer? Q4: What are the barriers that keep people from getting screened for hepatitis and liver cancer and how can they be addressed? Q5: What can people living with chronic hepatitis B and C do to protect their liver health and prevent liver cancer? Q6: Why are some populations more vulnerable to viral hepatitis and liver cancer, and how do we address the disparities? Q7: What can we do to raise awareness & educate vulnerable communities about viral hepatitis and its link to liver cancer? Q8: What resources are available to learn more about viral hepatitis and liver cancer? Co-hosts and special guests for the chat include: Hepatitis B Foundation - @hepbfoundation NASTAD - @NASTAD CDC Division of Viral Hepatitis - @cdchep CDC Cancer - @cdc_cancer Dr. Katherine McGlynn - National Cancer Institute, Division of Cancer Epidemiology and Genetics - @NCIEpiTraining CDC National Prevention Information Network (CDCNPIN) will

    http://www.hepb.org/blog/prioritizing-liver-cancer-people-living-viral-hepatitis-liver-cancer-awareness-twitter-chat/
  • “How Did You Get Hepatitis B?” Why We Should Answer

    Image courtesy of Serge Bertasius Photography at FreeDigitalPhotos.net By Christine Kukka Telling someone you have hepatitis B is almost always followed by the question, “how did you get it?” The question can feel like an invasion of privacy or an indictment. Behind the question lurks a desire for reassurance that hepatitis B won't happen to them, but of course it can. And that's why we should answer and tell our story. On a global scale, the story of hepatitis B is the story of humanity. How we and our forebears became infected results from centuries of human migrations, the transatlantic slave trade, political upheaval, poverty, re-used medical devices and ineffective public health policies. Our stories are the result of those global trends. But do we have to share when telling them makes us feel powerless (my mother had it and there was no vaccine where I was born), or like a victim (health workers re-used syringes on me), or just stupid (I didn’t practice safe sex)? Because hepatitis B happens to “innocent” people, especially children, people want to find fault and stigmatize the infected. It's a common response, the more innocent victims of crime or disease are, the more threatened and unsettled they make us feel. They remind us that we live in an arbitrary and cruel world no matter how much we play by the rules. To avoid that reality we “blame the victim” and assume disease could never happen to us or someone we love. The HIV epidemic and the government’s slow response illustrate the dangers of such denial. But despite widespread prejudice, people with HIV began to tell their stories. They knew education and awareness would prevent new infections and speed the search for a cure. Their stories gave a human face to HIV infection. The infected became what they always were: our neighbors, friends and family members. An HIV blog recently asked members to share how they became infected. One man wrote, “On the one hand, we all know that it

    http://www.hepb.org/blog/how-did-you-get-hepatitis-b-why-we-should-answer/
  • Peter Block, MD, MSc

      Clinical Fellow Yale School of Medicine  Dr. Block is a clinical fellow in gastroenterology and hepatology at the Yale School of Medicine. He completed his medical training and graduate education at Thomas Jefferson University and Oxford University, respectively. His clinical and research interests center on health outcomes in patients with viral hepatitis, cirrhosis, and hepatocellular carcinoma.  Read the journal picks of the month from our Emerging Scholars Scientific and Medical Advisory Board here.  

    https://www.hepb.org/news-and-events/reports/emerging-scholars-scientific-and-medical-advisors/peter-block-md-msc/
  • It's Time to Take On the Deadliest Cancers

    … most deadly cancers. The Hepatitis B Foundation, with its dedicated liver cancer program, Liver Cancer Connect, is a  Coalition member. The Coalition helped pass the 2012 Recalcitrant Cancer Research Act, which received broad bipartisan and bicameral support. The Act calls on the National Cancer Institute to develop strategies for earlier detection methods and better treatments for the deadliest cancers. To keep up the momentum and intensify efforts to heighten awareness of the deadliest cancers, the Coalition recently organized a congressional briefing with the newly formed Congressional Caucus on the Deadliest Cancers, which is chaired by Representatives Leonard Lance (R-NJ), Anna Eshoo (D-CA), Dave Reichert (R-WA) and Henry Waxman (D-CA). The goal of the Coalition is to raise funds for comprehensive private research and advocate for dedicated federal research to develop early diagnostics and better treatments, and increase chances of survival. A concerted effort by all stakeholders— policy makers, scientists, clinicians, and the public—can change the alarming recent predictions and improve the future outlook for people with the deadliest cancers. But research takes time and long-term commitment. Which is why we need to act now.

    http://www.hepb.org/blog/its-time-to-take-on-the-deadliest-cancers/
  • Roadmap for a Cure

    We believe that the elimination of hepatitis B from the human population is possible with the right combination of prevention, education, and focus on treatment. To achieve this ambitious goal, we solicited input from more than 30 of the world's leading experts to develop a detailed research agenda that we believe will lead us to a cure.  We have condensed our research agenda, with information on priority research areas and potential funding, into an overview Roadmap for a Cure.  For a hard copy of the Roadmap, or for the full-length versions of the manuscripts the Roadmap is based on, please email info@hepb.org or call 215-489-4900.   Additional Resources Hepatitis B Cure Campaign 2018 Progress Report List of 2018 Hep B United partners in our advocacy efforts

    https://www.hepb.org/research-and-programs/advocacy/roadmap-to-a-cure/
  • John's Story

    When he was 16, John learned during a routine medical checkup that he has hepatitis B. After his mother reacted with tears and concern, he decided that he needed to demonstrate to himself and others that people living with the virus can live full, adventurous lives. John decided to organize a charity bike ride to raise money for hepatitis B research. The support he received from people following his journey from Florida to Pennsylvania gave him the strength necessary to endure an often-exhausting cycling experience.    

    https://www.hepb.org/research-and-programs/patient-story-telling-project/johns-story/
  • Espi's Story

    Espi found out that she has hepatitis B when she was 64. For some time, she was monitored every six months, but eventually a doctor told her she could die if she didn’t begin treatment. Instead of automatically taking his advice, she researched her options. She also kept active, ate well, and tried not to worry. Finding a support group helped her to decide on her own terms to take medication, when she had all the information she needed. Espi's story is available in English and Tagalog.   English   Tagalog

    https://www.hepb.org/research-and-programs/patient-story-telling-project/espis-story/
  • Binh's Story

    When Binh found out he has hepatitis B, his youth and good health led him to put off any follow-up. Several years later, Binh learned his viral load was very high and fortunately started treatment “not a moment too soon.” Binh’s experience highlights the need for more advocacy around hepatitis B testing and treatment and more education about the silent nature of the disease.  

    https://www.hepb.org/research-and-programs/patient-story-telling-project/binhs-story/